5-aza-2 ′-deoxycytidine, a dna methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 5, 2014, Pages 463-476

  Azechi, Takuya ^a   Sato, Fumiaki ^a   Sudo, Ryo ^a   Wachi, Hiroshi ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

5 aza 2 deoxycytidine; Alkaline phosphatase; DNA methylation; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKALINE PHOSPHATASE; ALPHA SMOOTH MUSCLE ACTIN; BISULFITE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CPG OLIGODEOXYNUCLEOTIDE; DNA DIRECTED RNA POLYMERASE III; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSTEOPONTIN; PHOSPHATE; SODIUM PHOSPHATE COTRANSPORTER; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR RUNX2; TRANSGELIN; AZACITIDINE; DECITABINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; PHOSPHORUS; RNA;

ARTICLE; BLOOD VESSEL CALCIFICATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME REPRESSION; GENE; HUMAN; HUMAN CELL; MINERALIZATION; MRNA EXPRESSION ASSAY; OSTEOGENIC GENE; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; AORTA; BIOSYNTHESIS; CELL CULTURE; COMPARATIVE STUDY; GENETICS; METABOLISM; PATHOLOGY;

ALKALINE PHOSPHATASE; AORTA; AZACITIDINE; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; HUMANS; MUSCLE, SMOOTH, VASCULAR; PHOSPHORUS; REAL-TIME POLYMERASE CHAIN REACTION; RNA; VASCULAR CALCIFICATION;

EID: 84901503661     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.20818     Document Type: Article

References (56)

1. Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res, 2006; 99: 1044-1059.
2. Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, Naves-Díaz M, Díaz-López B: Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol, 2006; 17: S267-S273.
3. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant, 2003; 18: 1731-1740.
4. Sigrist M, Bungay P, Taal MW, Mclntyre CW: Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant, 2006; 21: 707-714.
5. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 2000; 342: 1478-1483.
6. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol, 2005; 16: 520-528.
7. Shao JS, Cai J, Towler DA: Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol, 2006; 26: 1423-1430.
8. Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol, 2008; 19: 213-216.
9. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM: Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res, 2011; 109: 697-711.
10. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int, 2009; 75: 1297-1307.
11. Pai A, Leaf EM, El-Abbadi M, Giachelli CM: Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol, 2011; 178: 764-773.
12. Dalfino G, Simone S, Porreca S, Cosola C, Balestra C, Manno C, Schena FP, Grandaliano G, Pertosa G: Bone morphogenetic protein-2 may represent the molecular link between oxidative stress and vascular stiffness in chronic kidney disease. Atherosclerosis, 2010; 211: 418-423.
13. Li X, Yang HY, Giachelli CM: BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis, 2008; 199: 271-277.
14. Tajima S, Suetake I: Regulation and function of DNA methylation in vertebrates. J Biochem, 1998; 123: 993-999.
15. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev, 2002; 16: 6-21.
16. Meehan RR: DNA methylation in animal development. Semin Cell Dev Biol, 2003; 14: 53-65.
17. Geiman TM, Robertson KD: Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem, 2002; 87: 117-125.
18. Eslaminejad MB, Fani N, Shahhoseini M: Epigenetic regulation of osteogenic and chondrogenic differentiation of mesenchymal stem cells in culture. Cell J, 2013; 15: 1-10.
19. Bestor TH: The DNA methyltransferase of mammals. Hum Mol Genet, 2000; 9: 2395-2402.
20. Jeltsch A: Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem, 2002; 3: 274-293.
21. Robertson KD: DNA methylation and human disease. Nat Rev Genet, 2005; 6: 597-610.
22. Issa JP: Aging, DNA methylation and cancer. Crit Rev Oncol Hematol, 1999; 32: 31-43.
23. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases. Biochem Biophys Acta, 2007; 1775: 138-162.
24. Lorenzen JM, Martino F, Thum T: Epigenetic modification in cardiovascular disease. Basic Res cardiol, 2013; 107: 245.
25. Teven CM, Liu X, Hu N, Tang N, Kim SH, Huang E, Yang K, Li M, Gao JL, Liu H, Natale RB, Luther G, Luo Q, Wang L, Rames R, Bi Y, Luo J, Luu HH, Haydon RC, Reid RR, He TC: Epigenetic regulation of mesenchymal stem cells: a focus on osteogenic and adipogenic differentiation. Stem Cells Int, 2011; 2011: 201371.
26. Zhou GS, Zhang XL, Wu JP, Zhang RP, Xiang LX, Dai LC, Shao JZ: 5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation. Cytotechnology, 2009; 60: 11-22.
27. Zhang RP, Shao JZ, Xiang LX: GADD45A protein plays an essential role in active DNA demethylation during terminal osteogenic differentiation of adipose-derived mesenchymal stem cells. J Biol Chem, 2011; 286: 41083-41094.
28. Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B: Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res, 2010; 38: 4313-4324.
29. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST: 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol, 2005; 25: 4727-4741.
30. Laurenzana A, Petruccelli LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, Miller WH Jr: Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Res, 2009; 69: 55-64.
31. Weinreb M, Shinar D, Rodan GA: Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res, 1990; 5: 831-842.
32. Doherty MJ, Schlag G, Schwarz N, Mollan RA, Nolan PC, Wilson DJ: Biocompatibility of xenogeneic bone, commercially available coral, a bioceramic and tissue sealant for human osteoblasts. Biomaterials, 1994; 15: 601-608.
33. Delgado-Calle J, Sañudo C, Sánchez-Verde L, García- Renedo RJ, Arozamena J, Riancho JA: Epigenetic regulation of alkaline phosphatase in human cells of the osteoblastic lineage. Bone, 2011; 49: 830-838.
34. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC: Localization of osteoprotegerin, tumor necrosis factor-related apoptosisinducing ligand, and receptor activator of nuclear factorkappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004; 89: 4104-4112.
35. Son BK, Akishita M, Iijima K, Eto M, Ouchi Y: Mechanism of Pi-induced vascular calcification. J Atheroscler Thromb. 2008; 16: 63-68.
36. Lau WL, Festing MH, Giachelli CM: Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost, 2010; 104: 464-470.
37. Li X, Yang HY, Giachelli CM: Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res, 2006; 98: 905-912.
38. Mune S, Shibata M, Hatamura I, Saji F, Okada T, Maeda Y, Sakaguchi T, Negi S, Shigematsu T: Mechanism of phosphate-induced calcification in rat aortic tissue cul- ture: possible involvement of Pit-1 and apoptosis. Clin Exp Nephrol, 2009; 13: 571-577.
39. Hui M, Li SQ, Holmyard D, Cheng P: Stable transfection of nonosteogenic cell line with ALP enhances mineral deposition in the presence and absence of β-glyserophosphate: possible role for alkaline phosphatase in pathological mineralization. Calcif Tissue Int, 1997; 60: 467-472.
40. Azechi T, Kanehira D, Kobayashi T, Sudo R, Nishimura A, Sato F, Wachi H: Trichostatin A, an HDAC Class I/II Inhibitor, Promotes Pi-Induced Vascular Calcification Via Up-Regulation of the Expression of Alkaline Phosphatase. J Atheroscler Thromb, 2013; 20: 538-547.
41. Speer MY, Li X, Hiremath PG, Giachelli CM: Runx2/ Cbfa1, but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem, 2010; 110: 935-947.
42. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabunciyan S, Feinberg AP: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet, 2009; 41: 178-186.
43. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002; 3: 415-428.
44. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza- 2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004; 103: 1635-1640.
45. Kan PX, Popendikyte V, Kaminsky ZA, Yolken RH, Petronis A: Epigenetic studies of genomic retroelements in major psychosis. Schizophr Res, 2004; 67: 95-106.
46. Kato C, Petronis A, Okazaki Y, Tochigi M, Umekage T, Sasaki T: Molecular genetic studies of schizophrenia: challenges and insights. Neurosci Res, 2002; 43: 295-304.
47. Nath KA: The tubulointerstitium in progressive renal disease. Kindey Int, 1998; 54: 992-994.
48. Sun CY, Chang SC, Wu MS: Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int, 2012; 81: 640-650.
49. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med, 2010; 16: 544-550.
50. Westerberg PA, Linde T, Wikström B, Ljunggren O, Stridsberg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant, 2007; 22: 3202-3207.
51. Ambrus C, Molnar MZ, Czira ME, Rosivall L, Kiss I, Remport A, Szathmari M, Mucsi I: Calcium, phosphate and parathyroid metabolism in kidney transplanted patients. Int Urol Nephrol, 2009; 41: 1029-1038.
52. Choi JH, Nam KH, Kim J, Baek MW, Park JE, Park HY, Kwon HJ, Kwon OS, Kim DY, Oh GT: Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25: 2404-2409.
53. Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, Ishikawa Y, Yokoyama M: Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb, 2006; 13: 183-191.
54. Findeisen HM, Gizard F, Zhao Y, Qing H, Heywood EB, Jones KL, Cohn D, Bruemmer D: Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol, 2011; 31: 851-860.
55. Choi JH, Nam KH, Kim J, Baek MW, Park JE, Park HY, Kwon HJ, Kwon OS, Kim DY, Oh GT: Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25: 2404-2409.
56. Takemura A, Iijima K, Ota H, Son BK, Ito Y, Ogawa S, Eto M, Akishita M, Ouchi Y: Sirtuin 1 retards hyperphosphatemia- induced calcification of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2011; 31: 2054-2062